One In Ten
1 in 10 people will experience problems with their liver at some point in their life.
Help us FIGHT liver disease.
I am a Clinician Scientist focusing on investigating the gut-liver axis in advanced chronic liver disease, including the pathophysiological roles of the gut microbiome and intestinal barrier in driving infection risk and antimicrobial resistance, and therapeutic interventions that can target these areas. Linked to this are how metabolic profiling and other high throughput systems biology-based techniques can further elucidate the mechanisms behind these changes and harnessing this knowledge can facilitate the development of better targeted therapies. Chronic liver disease is a condition which I am dedicated to managing clinically and still represents so much unmet need. Translational research in this area is therefore pivotal to improving patient outcomes and quality of life in those that are afflicted, and my group is determined to make real progress in this area.
Contact Dr Vish Patel: firstname.lastname@example.org
Research Assistant in the Institute: Betsy Arefaine
Dr Saeed Shoaie (Centre for Host Microbial Interactions, King’s College London and NGI, Karolinska, Sweden); Dr Lindsay Hall (Quadram Institute, Norwich); Dr Mark J W McPhail (King’s College London); Dr Lindsey A Edwards (King’s College London); Dr Kenneth Bruce (King’s College London); Prof Debbie Shawcross (King’s College London); Prof William Bernal (King’s College Hospital); Prof Ton Lisman (UMCH, Groeningen, Netherlands); Prof Mark Thursz (Imperial College London); Dr Sidsel Støy (Aarhus University, Denmark); Dr Guatam Mehta (Institute of Hepatology, FLR, London); Dr Jane Cox (Institute of Hepatology, FLR, London); Dr Shilpa Chokshi (Institute of Hepatology, FLR, London)
Annabel Blasi*, Vishal C. Patel*, Jelle Adelmeijer, Javier Fernández, William Bernal†, Ton Lisman†. Mixed fibrinolytic phenotypes in decompensated cirrhosis and ACLF with hypo fibrinolysis in those with poor outcome. Hepatology. 2019 Aug 29. doi: 10.1002/hep.30915 [Epub ahead of print] (*indicates joint first authorship, †indicates joint senior authorship)
Annabel Blasi*, Vishal C. Patel*, Jelle Adelmeijer, Sarah Azarian, Fatima Aziz, Javier Fernández, William Bernal, Ton Lisman. Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. JHEP Reports 2019, doi:10.1016/j.jhepr.2019.06.002 (*indicates joint first authorship)
Woodhouse CA, Patel VC, Goldenberg S, Sanchez-Fueyo A, China L, O’Brien A, Flach A, Douiri D, Shawcross DL. PROFIT, a PROspective, randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. BMJ Open 2019;9:e023518. doi:10.1136/bmjopen-2018-023518
A Riva, VC Patel, K Mehta, C Lopez, G Wright, S Tarff, A Evans, D Shawcross, J Ryan, R Williams, S Chokshi: Mucosa-associated invariant T-cells link intestinal immunity with antibacterial immune defects in Alcoholic Liver Disease. Gut. 2017 Nov 2. pii: gutjnl-2017-314458. doi: 10.1136/gutjnl-2017-314458.
C Fisher*, VC Patel*, S Stoy, A Singanayagam, J Adelmeijer, J Wendon, DL Shawcross, T Lisman†, W Bernal†: Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. Journal of Critical Care 08/2017; 43., DOI:10.1016/j.jcrc.2017.07.053 (*indicates joint first authorship, † indicates joint last authorship)
Vishal C Patel, Helen White, Sidsel Støy, Jasmohan S Bajaj, Debbie L Shawcross: Clinical science workshop: targeting the gut-liver-brain axis. Metabolic Brain Disease 10/2015; DOI:10.1007/s11011-015-9743-4
Vishal C. Patel, Debbie L. Shawcross: Salivary microbiota-immune profiling in cirrhosis: Could this be the non-invasive strategy that will revolutionize prognostication in hepatology? Hepatology 05/2015; 62(4). DOI:10.1002/hep.27870
The Foundation runs on donations. Every little helps us continue our work.